Post by Aphaia Pharma

Our CSO, Steffen-Sebastian Bolz, recently spoke with Lucie Ellis-Taitt of Citeline about our patient-first vision for obesity care and how our oral glucose formulation is designed to re-engage the gut’s natural nutrient-sensing network to support sustainable weight control. Read the article below to learn more about how our approach aims to redefine obesity treatment by prioritizing patient experience and leveraging the body’s physiological mechanisms, rather than focusing on maximal weight loss alone. https://bit.ly/44A2pIV